[Clinical effect of the combined use of aztreonam, amikacin and clindamycin in infectious disease in obstetrics and gynecology].
Clinical effects of combined use of aztreonam (AZT), amikacin (AMK) and clindamycin (CLDM) in 46 cases with infectious diseases in obstetrics and gynecology were retrospectively studied in 2 groups, and the following results were obtained. 1. No significant difference in efficacy rates was noted between AZT plus CLDM treated group (n = 25) and AMK plus CLDM treated group (n = 21) (96.0% vs. 95.2%), while rate of excellent efficacy was slightly higher in AZT plus CLDM group than AMK plus CLDM group (24.0% vs. 14.3%). 2. No significant difference in bacteriological clinical effects was also noted between the 2 groups, while bacteriological eradication rate was higher in the AZT plus CLDM group than in the other group (76.2% vs. 50.0%), and the difference was particularly clear in the eradication rates of aerobic, Gram-negative bacteria (88.9% vs. 30.0%). 3. Subjective and objective side effects, and abnormalities of clinical test results were not found in either group.
Chimura
T
T
Department of Obstetrics and Gynecology, School of Medicine, Yamagata University.
Satou
S
S
Funayama
T
T
Oono
T
T
Sakai
Y
Y
Morisaki
N
N
Kanasugi
H
H
Takahashi
H
H
Saitou
N
N
Miyata
R
R
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000627:therapeutic use*; D001398:Aztreonam / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology; D002981:Clindamycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000453:epidemiology; D012189:Retrospective Studies
D002981:Clindamycin; D000583:Amikacin; D001398:Aztreonam